Medullary Thyroid Carcinoma clinical trials

Explore recruiting medullary thyroid carcinoma clinical trials.

Recruiting medullary thyroid carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Medullary Thyroid Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Digoxin for the Reinduction or Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma.

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Medullary Thyroid Carcinoma trials by city

Medullary Thyroid Carcinoma clinical trials

Recruiting medullary thyroid carcinoma studies right now

Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers

Also recruiting in Europe

Digoxin for the Reinduction or Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma.

Medullary Thyroid Carcinoma trials by city

Other conditions